Shilpa Medicare Ltd. News and Updates

Name: Latest research reports of Shilpa Medicare Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Shilpa Medicare Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Shilpa Medicare Ltd. from all sources in a single place.

Load latest

Shilpa Medicare Ltd.

11 Jul 2018

937.10

5.00%

Shilpa Medicare gets EIR for Raichur unit; stock rallies 14%

Business Line

Shares of Shilpa Medicare Ltd jumped as much as 13.8 per cent to Rs 434, their highest since May 29. The stock posted its biggest intraday percentage

Shilpa Medicare Ltd. has gained 20.72% in the last 6 Months

Shilpa Medicare surges 13% after receiving EIR from USFDA

Business Standard | 11 Jul 2018

Shilpa Medicare Ltd.

28 May 2018

937.10

5.00%

Base business remains healthy; ANDA approvals - key for overall growth

Buy: Shilpa Medicare Ltd.

Target

Motilal Oswal

28 May 2018 Net sales grew 3.8% YoY to INR2.3b (est. of INR2.1b) in 4QFY18, led by increased formulation sales. Gross margin shrank 500bp YoY to 54% due to increased RM prices in the CRAMS business. EBITDA margin, too, contracted 480bp YoY to 20.3% (est. This, along with higher depreciation and lower other income, led to a PAT decline of 23.5% YoY to INR304m (est. Sales were flat at INR7.9b, largely due to the transfer of the CRAMS business to a joint venture.

Shilpa Medicare Ltd. has gained 20.72% in the last 6 Months

Shilpa Medicare Ltd.

02 Apr 2018

937.10

5.00%

Shilpa Medicare: Stake sale to mark end of JV with ICE

Buy: Shilpa Medicare Ltd.

Target

Motilal Oswal

Shilpa Medicare (SLPA) recently decided to end its joint venture (JV) with ICE S.P.A Italy (ICE) - a move that would help it garner proceeds of INR1.3b, as against its investment of INR800m toward the JV. Furthermore, the amount of annual business with ICE via CRAMS may be reduced by ~INR500m. The decision was premised on the increasing uncertainty over the profitability of the JV. Accordingly, for FY19/FY20, we reduce our (i) sales estimate by 5% to INR10b/INR12b and (ii) earnings estimate by 8.5% to INR2.1b/INR2.7b. Consequently, our price target is lowered to INR686 (25x 12M forward earnings). We, however, remain positive on SLPA and re-iterate our Buy rating, given the promising outlook for the US formulations business (31 ANDAs pending for approval)and minimal medium-term regulatory risk.

Number of FII/FPI investors increased from 114 to 121 in Mar 2025 qtr.

Shilpa Medicare Ltd.

27 Mar 2018

937.10

5.00%

Shilpa Medicare Ltd.

Buy: Shilpa Medicare Ltd.

AUM Capital

Shilpa Medicare Ltd. (SML), established in 1987 at Raichur, Karnataka is engaged in the production and exports of consistently high-quality Active Pharmaceutical Ingredients (API) Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications with Mr. Omprakash Inani as Chairman and Mr. Vishnukant C. Bhutada as MD. Over the period of time, it has shifted its focus towards creating a niche in pharmaceutical manufacturing particularly in Oncology generics. It is one of the leaders in the Oncology market and offers a complete range of products in this segment spanning across APIs, formulations both in terms of R&D; and manufacturing capabilities along...

Shilpa Medicare Ltd. is trading above all available SMAs

Shilpa Medicare Ltd.

19 Mar 2018

937.10

5.00%

Shilpa Medicare climbs 7% on receiving EIR

Economic Times

The facility was inspected between November 11 and November 30, 2017.

Shilpa Medicare Ltd.'s price crossed above 30Day SMA today

Shilpa Medicare gains 7% on EIR for Jadcherla formulations unit

Business Standard | 19 Mar 2018

Shilpa Medicare Ltd.

19 Mar 2018

937.10

5.00%

Shilpa Medicare : EIR lowers regulatory risk over medium term

Buy: Shilpa Medicare Ltd.

Motilal Oswal

The receipt of establishment inspection report (EIR), with unchanged status - voluntary action initiated (VAI) - for the Jadcherla formulations facility from the USFDA is a positive. It minimizes regulatory risk over the medium term. SLPA's ANDA pipeline remains robust. We expect 16% CAGR in sales to INR12b and 35% CAGR in PAT to INR2.7b over FY17-20. Our price target of INR749 implies 53% upside. We re-iterate Buy

Shilpa Medicare Ltd. is trading above all available SMAs

Shilpa Medicare Ltd.

13 Feb 2018

937.10

5.00%

Shilpa Medicare : One-offs led weak results; Outlook remains promising

Buy: Shilpa Medicare Ltd.

Target

Motilal Oswal

We have reduced our EPS estimates by 26%/11%/11% for FY18E/19E/20E to factor 1) increased RM prices in CRAMS and 2) deferment of US business due to inspection related hurdle and equipment related issue. Accordingly, we have revised our price target to INR749 (from INR797 earlier) by valuing at 25x 12m forward earnings.Though Q3FY18 results were weak, we remain positive as SLPA has robust ANDA pipeline for US market, which is the key growth driver, subject to approval. Maintain Buy on potential upside of 47% from current levels

Shilpa Medicare Ltd. is trading above all available SMAs

Shilpa Medicare Ltd.

30 Jan 2018

937.10

5.00%

Company News: Shilpa Medicare

Business Line

Shilpa Medicare's bulk drugs units in Raichur, Karnataka, violated the same manufacturing norm of the US Food and Drug Administration for the second inspection in a row, a Cogencis

Shilpa Medicare Ltd. has gained 43.25% in the last 1 Year

Shilpa Medicare Ltd.

22 Jan 2018

937.10

5.00%

US FDA completes inspection of Shilpa Medicare Raichur units

Business Line

Shilpa Medicare has informed the exchanges that the US FDA has completed inspection of the company's API Unit-I and Unit-II at Raichur, Karnataka, between January 16 and 19. The FDA concluded the...